Five things for pharma marketers to know: Thursday, August 3, 2017

Share this content:


1. An FDA advisory panel recommended against approving Johnson and Johnson's experimental arthritis drug sirukumab by a vote of 12-1. The committee cited safety concerns, specifically the number of patients who died compared to those taking the placebo during clinical trials. (Reuters)

2. Scientists successfully edited genes in human embryos for the first time, using CRISPR, which is gene-editing technology, according to a study published in Nature. Researchers were able to fix a gene mutation in embryos that causes a common heart condition. (NYT)

3. Shire told investors that the company may spin off its ADHD business into a new public company. The remaining business would focus on rare diseases. (Endpoints News)

4. Theranos reached an agreement to settle a lawsuit with Walgreens Boots Alliance. Walgreens had alleged that Theranos breached a contract putting 40 Theranos blood-testing centers in its stores. (WSJ)

5. 23andMe and Lundbeck plan to create a 25,000-person study to investigate the role of genetics in depression. (BioPharmaDIVE)

Share this content:
Scroll down to see the next article